10-Q: Kairos Pharma Q1 2026 Financial Results and Outlook

Kairos Pharma reports a net loss of $1.65 million for Q1 2026 as it continues clinical development of its oncology pipeline.

Summary

• Reported a net loss of $1.65 million for the three months ended March 31, 2026, compared to a $1.26 million loss in the same period of 2025.
• Operating expenses increased to $1.69 million, driven by higher research and development costs and public company administrative expenses.
• Cash and cash equivalents stood at $3.68 million as of March 31, 2026.
• Raised $385,000 in gross proceeds through an At-the-Market (ATM) offering during the quarter.
• Entered into a binding term sheet to acquire CL-273, a pan-EGFR inhibitor, for 16.5% of outstanding capital stock and future milestones.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative report due to the persistent going-concern warning, lack of revenue, and identified material weaknesses in internal controls, despite the expansion of the pipeline.

Positives

• Successfully raised capital through an ATM offering to support ongoing operations.
• Expanded the product pipeline through the proposed acquisition of the CL-273 asset.
• Secured a new pharmaceutical development services agreement with Patheon to support Phase II clinical trials.

Negatives

• Reported a net loss of $1.65 million for the quarter with no revenue generated.
• Operating expenses rose by approximately 33% year-over-year.
• Accumulated deficit reached $15.92 million as of March 31, 2026.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern due to recurring losses and limited cash runway.
• Existing cash balance may not be sufficient to fund operations for the next 12 months.
• Clinical trial outcomes are highly uncertain and may require more capital than currently estimated.
• Material weakness in internal controls over financial reporting remains, specifically regarding segregation of duties and review procedures.

Future Outlook

The company expects to continue incurring significant operating losses as it advances its product candidates through clinical development. It plans to finance future needs through equity or debt offerings, collaborations, or licensing arrangements, noting that existing cash may not cover the next 12 months of operations.

Management Comments

• Management acknowledges substantial doubt regarding the company's ability to continue as a going concern.
• Management emphasizes that clinical trial outcomes are highly uncertain and cannot be accurately estimated.

Industry Context

StockSavvy.ai notes that Kairos Pharma is operating in a capital-intensive, high-risk segment of the biotech industry where early-stage companies frequently face going-concern warnings while relying on dilutive financing to fund clinical milestones.

Comparison to Industry Standards

• The company's reliance on ATM offerings and private placements is standard for small-cap, clinical-stage biotech firms.
• The ongoing material weakness in internal controls is a common hurdle for recently public, smaller reporting companies.

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• Dr. Ramachandran Murali, VP of R&D, is an inventor of technologies licensed from Cedars-Sinai Medical Center.

Stakeholder Impact

• Shareholders face potential dilution from future equity-based capital raises.
• Creditors and suppliers are subject to the company's liquidity risks.

Next Steps

• Continue Phase 2 clinical trials for ENV-105.
• Complete due diligence and negotiate a definitive acquisition agreement for CL-273.
• Remediate identified material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The stock is a high-risk speculative play. Investors should hold until there is more clarity on clinical trial progress and the company secures a more stable, non-dilutive funding path.

Keywords

biotechnology, oncology, immunotherapy, clinical trials, KAPA, drug resistance, capital raise